T. Rowe Price Associates’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23.7M | Buy |
420,275
+61,085
| +17% | +$3.98M | ﹤0.01% | 1000 |
|
|
2025
Q4 | $28.8M | Sell |
359,190
-3,509
| -1% | -$236K | ﹤0.01% | 970 |
|
|
2025
Q3 | $17.7M | Buy |
362,699
+1,257
| +0.3% | +$77.8K | ﹤0.01% | 1081 |
|
|
2025
Q2 | $27M | Buy |
361,442
+4,260
| +1% | +$282K | ﹤0.01% | 893 |
|
|
2025
Q1 | $22.7M | Buy |
357,182
+2,901
| +0.8% | +$197K | ﹤0.01% | 927 |
|
|
2024
Q4 | $27.7M | Buy |
354,281
+25,617
| +8% | +$2.06M | ﹤0.01% | 912 |
|
|
2024
Q3 | $26.4M | Sell |
328,664
-19,397
| -6% | -$1.57M | ﹤0.01% | 933 |
|
|
2024
Q2 | $28.8M | Sell |
348,061
-214,393
| -38% | -$18.9M | ﹤0.01% | 862 |
|
|
2024
Q1 | $48M | Buy |
562,454
+156,665
| +39% | +$12.3M | 0.01% | 736 |
|
|
2023
Q4 | $34.7M | Sell |
405,789
-114,335
| -22% | -$9.88M | ﹤0.01% | 802 |
|
|
2023
Q3 | $46.6M | Sell |
520,124
-1,365
| -0.3% | -$122K | 0.01% | 706 |
|
|
2023
Q2 | $44.4M | Buy |
521,489
+35,733
| +7% | +$3.02M | 0.01% | 737 |
|
|
2023
Q1 | $40.2M | Buy |
485,756
+251
| +0.1% | +$20.3K | 0.01% | 742 |
|
|
2022
Q4 | $38.2M | Buy |
485,505
+79,532
| +20% | +$6.39M | 0.01% | 734 |
|
|
2022
Q3 | $30.1M | Buy |
405,973
+88,354
| +28% | +$6.34M | ﹤0.01% | 786 |
|
|
2022
Q2 | $20.7M | Buy |
317,619
+33,266
| +12% | +$1.97M | ﹤0.01% | 1158 |
|
|
2022
Q1 | $18M | Sell |
284,353
-40,007
| -12% | -$2.18M | ﹤0.01% | 1254 |
|
|
2021
Q4 | $17.2M | Sell |
324,360
-26,905
| -8% | -$1.64M | ﹤0.01% | 1317 |
|
|
2021
Q3 | $24.8M | Sell |
351,265
-205,049
| -37% | -$12.9M | ﹤0.01% | 1244 |
|
|
2021
Q2 | $37.1M | Buy |
556,314
+4,242
| +0.8% | +$300K | ﹤0.01% | 1131 |
|
|
2021
Q1 | $61.3M | Sell |
552,072
-55,960
| -9% | -$6.92M | 0.01% | 929 |
|
|
2020
Q4 | $72.2M | Sell |
608,032
-5,130
| -0.8% | -$552K | 0.01% | 835 |
|
|
2020
Q3 | $53.5M | Sell |
613,162
-10,811
| -2% | -$945K | 0.01% | 845 |
|
|
2020
Q2 | $55.9M | Sell |
623,973
-5,428
| -0.9% | -$548K | 0.01% | 815 |
|
|
2020
Q1 | $62.7M | Buy |
629,401
+3,491
| +0.6% | +$379K | 0.01% | 706 |
|
|
2019
Q4 | $71.9M | Sell |
625,910
-791
| -0.1% | -$95.7K | 0.01% | 778 |
|
|
2019
Q3 | $79.1M | Buy |
626,701
+23,178
| +4% | +$2.94M | 0.01% | 698 |
|
|
2019
Q2 | $72.6M | Buy |
603,523
+96,335
| +19% | +$9.48M | 0.01% | 752 |
|
|
2019
Q1 | $44.4M | Sell |
507,188
-51,445
| -9% | -$4.68M | 0.01% | 918 |
|
|
2018
Q4 | $55.9M | Sell |
558,633
-267,877
| -32% | -$28.1M | 0.01% | 783 |
|
|
2018
Q3 | $94.7M | Buy |
826,510
+267,321
| +48% | +$27.7M | 0.01% | 689 |
|
|
2018
Q2 | $50.1M | Sell |
559,189
-333,546
| -37% | -$28.2M | 0.01% | 896 |
|
|
2018
Q1 | $65.3M | Sell |
892,735
-631,487
| -41% | -$43.3M | 0.01% | 780 |
|
|
2017
Q4 | $88.5M | Sell |
1,524,222
-1,080,040
| -41% | -$56.9M | 0.01% | 687 |
|
|
2017
Q3 | $117M | Sell |
2,604,262
-625,424
| -19% | -$26M | 0.02% | 588 |
|
|
2017
Q2 | $128M | Sell |
3,229,686
-241,205
| -7% | -$9.91M | 0.02% | 533 |
|
|
2017
Q1 | $141M | Sell |
3,470,891
-1,931,040
| -36% | -$75.4M | 0.03% | 506 |
|
|
2016
Q4 | $217M | Sell |
5,401,931
-102,592
| -2% | -$3.87M | 0.04% | 408 |
|
|
2016
Q3 | $199M | Buy |
5,504,523
+133,393
| +2% | +$4.58M | 0.04% | 425 |
|
|
2016
Q2 | $156M | Buy |
5,371,130
+708,620
| +15% | +$21.4M | 0.03% | 461 |
|
|
2016
Q1 | $163M | Buy |
4,662,510
+1,988,730
| +74% | +$64.2M | 0.03% | 440 |
|
|
2015
Q4 | $86.2M | Buy |
2,673,780
+822,653
| +44% | +$26.7M | 0.02% | 595 |
|
|
2015
Q3 | $59.8M | Buy |
1,851,127
+51,927
| +3% | +$1.95M | 0.01% | 717 |
|
|
2015
Q2 | $74.4M | Buy |
1,799,200
+507,920
| +39% | +$21.4M | 0.02% | 696 |
|
|
2015
Q1 | $58M | Buy |
1,291,280
+6,200
| +0.5% | +$259K | 0.01% | 788 |
|
|
2014
Q4 | $48.1M | Buy |
1,285,080
+269,900
| +27% | +$9.89M | 0.01% | 851 |
|
|
2014
Q3 | $35.5M | Buy |
1,015,180
+999,000
| +6,174% | +$35.6M | 0.01% | 943 |
|
|
2014
Q2 | $571K | Sell |
16,180
-2,600
| -14% | -$86.9K | ﹤0.01% | 1888 |
|
|
2014
Q1 | $612K | Hold |
18,780
| – | – | ﹤0.01% | 1844 |
|
|
2013
Q4 | $791K | Buy |
18,780
+3,700
| +25% | +$152K | ﹤0.01% | 1739 |
|
|
2013
Q3 | $601K | Hold |
15,080
| – | – | ﹤0.01% | 1827 |
|
|
2013
Q2 | $624K | Buy |
+15,080
| New | +$611K | ﹤0.01% | 1790 |
|
Other funds holding HAE
VPM
VCM
RRAM
T. Rowe Price Associates's HAE Position: Q1 2026 in Review
T. Rowe Price Associates increased its Haemonetics (HAE) stake by 17% in Q1 2026, buying an estimated $3.98M and bringing the position to 420,275 shares worth $23.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1000.
T. Rowe Price Associates first reported a position in HAE in Q2 2013 and has held it in 52 quarters since. The position peaked at $217M in Q4 2016. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- T. Rowe Price Associates held 420,275 shares of Haemonetics worth $23.7M as of Q1 2026.
- T. Rowe Price Associates bought 61,085 Haemonetics shares in Q1 2026, an estimated $3.98M.
- Haemonetics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1000 holding.
- T. Rowe Price Associates first reported a position in Haemonetics in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Haemonetics position peaked at $217M in Q4 2016.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.